The Cambridge, MA-based developer of targeted cancer drugs sold about 5.9 million shares for $15 per share, hitting the high end of its proposed $13-$15 per share price range and exceeding previous fundraising targets for the offering.
The Cambridge, MA-based biotech company has proposed to raise up to $69 million in a public debut, with plans to spend proceeds from the deal on advancing clinical trials for its top candidates against cancer-related epigenetic enzymes.
The agreement follows the start of a Phase I study of the compound, EPZ-5676, for which biotech giant Celgene has partnered with the startup for development outside the U.S.
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.
The pact includes a commitment to pay tens of millions more in milestones for any successful therapies that come out of the deal.
Epigenetics is a new field in drug discovery. But one of the pioneers of the science has already struck a lucrative partnership pact with Roche's Genentech that could pave the way to a buyout.
Epizyme took in a $4 million in milestone payments from partner GlaxoSmithKline ($GSK) after achieving some pre-clinical goals in the epigenetic alliance announced in January 2010. With up to $630
With plenty of science to explore but limited funds, a biotech startup often faces the challenge of where to focus its time and money. At Constellation Pharmaceuticals , CEO Mark Goldsmith tells
Xconomy's Luke Timmerman spent some time with the CEO and CBO at Epizyme to see how the three-year-old biotech was able to score two impressive development deals with Big Pharma earlier this year.
Just weeks after GlaxoSmithKline committed up to $650 million in its epigenetics pact with Cambridge, MA-based Epizyme , Japan's Eisai has hopped on board the promising discovery platform with a $206